KaloBios (KBIO) Files For Bankruptcy After Ousting Shkreli

Mani

Published onDecember 30, 2015

Updated on May 13, 2021

KaloBios Pharmaceuticals filed for Chapter 11 bankruptcy Tuesday night, as first reported by ValueWalk, within two weeks of CEO Martin Shkreli’s arrest on securities fraud.

The drug maker’s latest move comes on the heels of its appeal of Nasdaq’s decision to delist its shares.

KaloBios Pharmctcls (KBIO) — Chart via S&P Capital IQ

KaloBios files for bankruptcy

KaloBios listed assets and liabilities in the range of $1 million to $10 million in a Chapter 11 filing late Tuesday with the U.S. bankruptcy court for the District of Delaware.

The San Francisco company’s largest creditors include the...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

KaloBios (KBIO) Files For Bankruptcy After Ousting Shkreli

KaloBios files for bankruptcy

Login required to continue reading.

Get Your Business News